Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis

J Neuroimmunol. 2020 Aug 15:345:577281. doi: 10.1016/j.jneuroim.2020.577281. Epub 2020 Jun 3.

Abstract

To identify the mechanisms relevant for the therapeutic effect of glatiramer acetate (GA), we studied T- and B- regulatory cells as well as GM-CSF expression in mice recovered from experimental autoimmune encephalomyelitis (EAE). Selective depletion of Tregs reduced but did not eliminate the ability of GA to ameliorate EAE, indicating a role for additional immune-subsets. The prevalence of Bregs in the periphery and the CNS of EAE-mice increased following GA-treatment. Furthermore, GA downregulated the pathological expression of GM-CSF, on both the protein and mRNA levels. These findings corroborate the broad immunomodulatory mechanism of action of GA in EAE/MS.

Keywords: B-regulatory cells (Bregs); Experimental autoimmune encephalomyelitis; Glatiramer acetate (GA); Granulocyte-macrophage colony-stimulating factor (GM-CSF); Multiple sclerosis; T-regulatory cells (Tregs).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes, Regulatory / drug effects
  • B-Lymphocytes, Regulatory / metabolism*
  • Disease Models, Animal
  • Female
  • Glatiramer Acetate / pharmacology*
  • Glatiramer Acetate / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism*
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism*
  • T-Lymphocytes, Regulatory / drug effects
  • T-Lymphocytes, Regulatory / metabolism*

Substances

  • Immunosuppressive Agents
  • Glatiramer Acetate
  • Granulocyte-Macrophage Colony-Stimulating Factor